Evidence map›Paper›PMID 38645231›Full record

ArticlebioRxiv : the preprint server for biology2024

Anna Kopp, Shujun Dong, Hyeyoung Kwon, Tiexin Wang, Alec A Desai, Jennifer J Linderman, Peter Tessier, Greg M Thurber

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Anna KoppDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109.
Shujun DongDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109.
Hyeyoung KwonDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109.
Tiexin WangDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109.
Alec A DesaiDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109.
Jennifer J LindermanDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109.
Peter TessierDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109.ORCID 0000-0002-3220-007X
Greg M ThurberDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109.ORCID 0000-0001-7570-2080
University of Michigan · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
NCI NIH HHS P30 CA046592
6 · The paper itself

Abstract

Antibody-drug conjugates (ADCs) have experienced a surge in clinical approvals in the past five years. Despite this success, a major limitation to ADC efficacy in solid tumors is poor tumor penetration, which leaves many cancer cells untargeted. Increasing antibody doses or co-administering ADC with an unconjugated antibody can improve tumor penetration and increase efficacy when target receptor expression is high. However, it can also reduce efficacy in low-expression tumors where ADC delivery is limited by cellular uptake. This creates an intrinsic problem because many patients express different levels of target between tumors and even within the same tumor. Here, we generated High-Avidity, Low-Affinity (HALA) antibodies that can automatically tune the cellular ADC delivery to match the local expression level. Using HER2 ADCs as a model, HALA antibodies were identified with the desired HER2 expression-dependent competitive binding with ADCs

Identifiers

PMID38645231
PMCPMC11030390
OpenAlexW4394675634

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.